

TRADERS NEWS SOURCE

New Breakout Alert: Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Revolutionary Drug in the Pipeline, Just One FDA Announcement Away from a Potential Moon Shot

"The company reported its fourth-quarter and full-year 2023 financial results, reaffirming the bioequivalence of PF614 to commercially available opioids but with reduced abuse potential. These results support the company's belief that PF614 will offer a safer, next-generation opioid option."

"Phase 3 clinical plans and the expedited clinical program due to the **FDA Breakthrough Therapy Designation.**" (Known as the Fast Track Designation)

Expecting News Soon...

Ensysce Biosciences, Inc. (NASDAQ: ENSC) has captured our attention with its notable volatility and potential for a significant catalyst any day now.

Technical Analysis

Historical Volatility and Current Opportunity

ENSC is known for experiencing substantial volatility over short periods. Currently, it presents a unique opportunity as it has significantly deviated from its 50-day moving average, creating a potential for upside.

Moving Average and RSI Indicators

ENSC's 50-day moving average stands at 0.69, more than 25% above Tuesday's closing price. Additionally, the Relative Strength Index (RSI) is at 39, suggesting the stock may be poised for an upward move if it maintains levels above its recent lows.

Company Overview

ENSC is a NASDAQ-listed clinical-stage company leveraging its proprietary technology platforms to develop safer prescription drugs. The company focuses on creating tamper-proof treatment options for pain that minimize the risks of drug abuse and overdose through its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms.

Current Price \$0.555/Share

Float 7.54m (According to DilutionTracker.com)

Daily Chart



Recent Developments

In February, Ensysce Biosciences announced a successful meeting with the FDA regarding PF614-MPAR, a next-generation opioid with overdose protection. This meeting provided valuable feedback for the non-clinical studies required for eventual new drug application (NDA) submission and approval, helping streamline the development of PF614-MPAR.

The FDA granted PF614-MPAR Breakthrough Therapy designation, facilitating more frequent meetings and access to FDA experts. PF614-MPAR combines PF614, a trypsin-activated abuse protection (TAAP) oxycodone prodrug, with a trypsin inhibitor, nafamostat, which inhibits the release of oxycodone when multiple doses are taken simultaneously.

CEO's Comments

Dr. Lynn Kirkpatrick, CEO of Ensysce, expressed gratitude for the FDA's guidance, emphasizing the critical nature of PF614-MPAR. **She highlighted the ongoing opioid crisis and the potential of their innovative opioid analgesic to reduce overdoses while providing better pain management.**

Financial Updates and Market Presence

Ensysce also received a positive Nasdaq listing determination, allowing it to continue its listing on The Nasdaq Capital Market tier until May 13, 2024, to demonstrate compliance with the equity requirement. *This could prove to be a major catalyst for the stock any day now.*

The company reported its fourth-quarter and full-year 2023 financial results, reaffirming the bioequivalence of PF614 to commercially available opioids but with reduced abuse potential. These results support the company's belief that PF614 will offer a safer, next-generation opioid option.

In April, Ensysce presented at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference and featured in Xtalks Clinical Edge Magazine.

Latest Announcements

Ensysce reported its first-quarter 2024 financial results, emphasizing PF614's Phase 3 clinical plans and the expedited clinical program due to the FDA Breakthrough Therapy designation.

Conclusion

With these developments and potential FDA catalysts, Ensysce Biosciences has good potential for a bounce and break above the 50-DMA which could trigger a further run. As always, ensure you conduct your own research before making any investment decisions.

The Team

Privacy Policy and Disclaimer

Your Consent

By using our site, you consent to our online privacy policy and disclaimer.

Do we disclose any information to outside parties?

We do not sell your information to anyone.

What information do we collect?

We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.

When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.

What do we use your information for?

When we collect your email or mobile number it is used for one purpose to send you the information you requested about small caps. Please read our disclaimer carefully before viewing our emails.

Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason, other than our CRM providers for the express purpose of delivering the information on stocks that you requested.

We send periodic emails.

The email address you provide may be used to send you information, the small cap reports you requested, respond to inquiries, and/or other requests or questions.

How do we protect your information?

We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.

Because we value your privacy, we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.

Online Privacy Policy

This online privacy policy applies to information collected through our website and social media platforms.

Contacting Us

If there are any questions regarding this privacy policy or disclaimer you may reply to this email.

Editor@TradersNewsSource.com

Disclaimer

Traders News Source is a wholly owned subsidiary of Media Source LLC, herein referred to as TNS LLC.

This website / media webpage is owned, operated and edited by Media Source LLC. Any wording found on this website / media webpage or disclaimer referencing to "I" or "we" or "our" or "TNS LLC" refers to Media Source LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for, these are issued for the purpose of building our brands. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. TNS LLC's business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding the publicly traded entities mentioned here. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.

Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator's , owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company's website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TNS LLC often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers' works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer's communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Some of our claims regarding gains could be based on intra-day, pre-market and after-hours trading data.

All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein.

Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.

TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in small and micro-cap growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information, and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. We have been compensated twelve thousand five hundred dollars cash via bank wire by TG MEDIA LLC for investor relations and marketing services of ENSC starting 05/15/2024 and lasting one day through 05/15/2024. We do not hold any form of equity in ENSC. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement.

TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.